BLOO7 schreef op 24 december 2018 00:31:
[...]
Waarom verschoven ze hun aandelen op 7 december 2017 in een nieuwe Europese firma?
Gilead Therapeutics A1 Unlimited Companyinvestors.gilead.com/static-files/992...Nog raarder:
Gilead Therapeutics A2 Unlimited CompanyGalapagos NV patent application (filgotinib)
www.gov.je/gazette/pages/patentapplic...5-phenyl-[1,2,4]triazolo[1,5-a]pyridin-2-yl-carboxamides as JAK inhibitors
An exclusive licence date Wednesday 14 March 2018 has been granted to: Gilead Therapeutics A2 Unlimited Company, of c/o Gilead Sciences